Therapeutic vaccination with vhs- herpes simplex virus reduces the severity of recurrent herpetic stromal keratitis in mice

Journal of General Virology

Volumn 83, Issue 10, 2002, Pages 2361-2365

  Keadle, Tammie L ^a   Laycock, Keith A ^a   Morris, Jessica L ^a   Leib, David A ^a   Morrison, Lynda A ^a   Pepose, Jay S ^a   Stuart, Patrick M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERPES SIMPLEX VACCINE; UNCLASSIFIED DRUG; VIRION HOST SHUTOFF PROTEIN; VIRUS ANTIBODY; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CORNEA OPACITY; DISEASE SEVERITY; EXPERIMENTAL MODEL; GENE DELETION; GENOTYPE; HEREDITY; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS; INCIDENCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; TIME; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION; VACCINATION; VIRION; VIRUS SHEDDING;

ANIMALIA; DNA VIRUSES; SIMPLEXVIRUS;

EID: 0036787163     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-83-10-2361     Document Type: Article

References (27)

1. Brubaker, J. O., Thompson, C. M., Morrison, L. A., Knipe, D. M., Siber, G. R. & Finberg, R. W. (1996). Induction of Th1-associated immune responses to beta-galaclosidase expressed by a replication-defective mutant of herpes simplex virus 1. Journal of Immunology 157, 1598-1604.
2. Daheshia, M., Kuklin, N., Kannangat, S., Manickan, E. & Rouse, B. T. (1997). Suppression of ongoing ocular inflammatory disease by topical administration of plasmid DNA encoding IL-10. Journal of Immunology 159, 1945-1952.
3. Deshpande, S. P., Kumaraguru, U. & Rouse, B. T. (2000). Why do we lack an effective vaccine against herpes simplex virus infections? Microbes and Infection 2, 973-978.
4. Geiss, B. J., Smith, T. J., Leib, D. A. & Morrison, L. A. (2000). Disruption of virion host shutoff activity improves the immunogenicity and protective capacity of a replication-incompetent herpes simplex virus type 1 vaccine strain. Journal of Virology 74, 11137-11144.
5. Keadle, T. L., Laycock, K. A., Miller, J. K., Hook, K. K., Fenoglio, E. D., Francotte, M., Slaoui, M., Stuart, P. M. & Pepose, J. S. (1997). Efficacy of a recombinant glycoprotein D subunit vaccine on the development of primary and recurrent ocular infection with herpes simplex virus type 1 in mice. Journal of Infectious Diseases 176, 331-338.
6. Keadle, T. L., Usui, N., Laycock, K. A., Kumano, Y., Pepose, J. S. & Stuart, P. M. (2001). Cytokine expression in murine corneas during recurrent herpetic stromal keratitis. Ocular Immunology and Inflammation 9, 193-205.
7. Keadle, T. L., Morrison, L. A., Morris, J. L., Pepose, J. S. & Stuart, P. M. (2002). Therapeutic immunization with a virion host shutoff-defective, replication-incompetent herpes simplex virus type 1 strain limits recurrent herpetic ocular infection. Journal of Virology 76, 3615-3625.
8. Kwong, A. D. & Frenkel, N. (1987). Herpes simplex virus-infected cells contain a function(s) that destabilizes both host and viral mRNAs. Proceedings of the National Academy of Sciences, USA 84, 1926-1930.
9. Lausch, R. N., Kleinschrodt, W. R., Monteiro, C., Kayes, S. G. & Oakes, J. E. (1985). Resolution of HSV corneal infection in the absence of delayed-type hypersensitivity. Investigative Ophthalmology & Visual Science 26, 1509-1515.
10. Laycock, K. A., Lee, S.F., Brady, R. H. & Pepose, J. S. (1991). Characterization of a murine model of recurrent herpes simplex viral keratitis induced by ultra violet B radiation. Investigative Ophthalmology & Visual Science 32, 2741-2746.
11. + T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. Journal of Experimental Medicine 191, 1459-1466.
12. Miller, J. K., Laycock, K. A., Umphress, J. A., Hook, K. K., Stuart, P. M. & Pepose, J. S. (1996). A comparison of recurrent and primary herpes simplex keratilis in NIH inbred mice. Cornea 15, 497-504.
13. Nesburn, A. B., Burke, R. L., Ghiasi, H., Slanina, S. M. & Wechsler, S. L. (1998). A therapeutic vaccine that reduces recurrent herpes simplex virus type 1 corneal disease. Investigative Ophthalmology & Visual Science 39, 1163-1170.
14. Niemialtowski, M. G. & Rouse, B. T. (1992). Predominance of Th1 cells in ocular tissue during herpetic stromal keratitis. Journal of Immunology 149, 3035-3039.
15. Pepose, J. S., Leib, D. A., Stuart, P. M. & Easty, E. L. (1996). Herpes simplex virus diseases: anterior segment of the eye. In Ocular Infection and Immunity, pp. 905-932. Edited by J. S. Pepose, G. A. N. Holland & K. R. Wilhelmus. St Louis, MO: Mosby.
16. Pivetti-Pezzi, P., Accorinti, M., Colabelli-Gisoldi, R. A., Pirraglia, M. P. & Sirianni, M. C. (1999). Herpes simplex virus vaccine in recurrent ocular infection. Cornea 18, 47-51.
17. Russell, R. G., Nasisse, M. P., Larsen, H. S. & Rouse, B. T. (1984). Role of T-lymphocytes in the pathogenesis of herpetic stromal keratitis. Investigative Ophthalmology & Visual Science 25, 938-944.
18. Shimeld, C., Hill, T. & Easty, D. (1989). An improved model of recurrent herpetic eye disease in mice. Current Eye Research 8, 1193-1205.
19. Shimeld, C., Hill, T., Blyth, W.A. & Easty, D. L. (1990). Passive immunization protects the mouse eye from damage after herpes simplex virus infection by limiting spread of virus in the nervous system. Journal of General Virology 71, 681-687.
20. Smith, T. J., Morrison, L. A. & Leib, D. A. (2002). Pathogenesis of herpes simplex virus type 2 virion host shutoff (vhs) mutants. Journal of Virology 76, 2054-2061.
21. Stanberry, L. R., Cunningham, A. L., Mindel, A., Scott, L. L., Spruance, S. L., Aoki, F. Y. & Lacey, C. J. (2000). Prospects for control of herpes simplex virus disease through immunization. Clinical Infectious Diseases 30, 549-566.
22. Strelow, L. I. & Leib, D. A. (1995). Role of the virion host shutoff (vhs) of herpes simplex virus type 1 in latency and pathogenesis. Journal of Virology 69, 6779-6786.
23. Stumpf, T. H., Shimeld, C., Easty, D. L. & Hill, T. J. (2001). Cytokine production in a murine model of recurrent herpetic stromal keratitis. Investigative Ophthalmology & Visual Science 42, 372-378.
24. Tigges, M. A., Leng, S., Johnson, D. C. & Burke, R. L. (1996). Human herpes simplex virus (HSV)-specific CD8 + CTL clones recognize HSV-2 infected fibroblasts after treatment with IFN-gamma or when virion host shutoff functions are disabled. Journal of Immunology 156, 3901-3910.
25. Tumpey, T. M., Elner, V. M., Chen, S., Oakes, J. E. & Lausch, R. N. (1994). Interleukin-10 treatment can suppress stromal keratitis induced by herpes simplex virus type 1. Journal of Immunology 153, 2258-2265.
26. Walker J. & Leib D. A. 1998 . Protection from primary infection and establishment of latency by vaccination with a herpes simplex virus type 1 recombinant deficient in virion host shutoff (vhs) function. Vaccine 16, 1-5.
27. Walker, J., Laycock, K. A., Pepose, J. S. & Leib, D.A. (1998). Post exposure vaccination with a virion host shutoff defective mutant reduces UV-B radiation-induced ocular herpes simplex virus shedding in mice. Vaccine 16, 6-8.